This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


DURECT Corporation

Drug Names(s): Transdermal sufentanil

Description: TRANSDUR-Sufentanil is a transdermal pain patch. Opioid analgesics such as sufentanil bind with stereospecific receptors at many sites within the central nervous system (CNS) to alter processes affecting both the perception of and emotional response to pain.

Deal Structure: TRANSDUR-Sufentanil was originally developed by DURECT.

In March 2005, DURECT entered into an agreement granting Endo exclusive rights to develop, market and commercialize the sufentanil patch in the U.S. and Canada.

In February 2009, Endo returned the U.S. and Canadaian rights to develop and commercialize TRANSDUR-Sufentanil to DURECT.

TRANSDUR-Sufentanil News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug